Chronic Lymphocytic Lymphoma, Issue 2, 2019 — Part 1: Our
interview with Prof Stilgenbauer highlights the following topics as
well as cases from his practice:
Updated International Workshop on Chronic Lymphocytic Leukemia
guidelines for diagnosis, indications for treatment, response
assessment and management of chronic lymphocytic leukemia (CLL)
(00:00)
Genetic abnormalities in CLL; effects of p53 mutations and 17p
deletion on prognosis and therapy (02:48)
Design and eligibility for the Phase III CLL14 trial of
venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for
patients with previously untreated CLL and coexisting medical
conditions (05:42)
Recent data from the Phase III iLLUMINATE, Alliance A041202 and
ECOG-E1912 trials comparing ibrutinib-based regimens to
chemoimmunotherapy as first-line treatment for patients with CLL
(07:51)
Results from the CLL14 trial comparing venetoclax to
chlorambucil as an addition to fixed-duration obinutuzumab therapy
for CLL (10:17)
Management of disease relapse on the CLL14 trial; role of
minimal residual disease (MRD) assessment in therapeutic
decision-making (13:19)
Dosing and administration of the recently FDA-approved
first-line regimen of venetoclax and obinutuzumab; mitigation of
risk for tumor lysis syndrome (16:03)
Mechanism of action of venetoclax; role of renal function in
the decision to administer this agent (17:02)
Emerging data with the combination of ibrutinib or venetoclax
with anti-CD20 antibodies (20:05)
Del(17p) and/or p53 mutation status and the selection of
therapy for patients with CLL (22:09)
Role of bendamustine/rituximab in the management of CLL
(26:43)
Perspective on the efficacy of venetoclax/obinutuzumab versus
ibrutinib as first-line therapy for patients with CLL (28:38)
Case: A man in his mid-60s with del(17p) CLL
and no IGHV mutation experiences a dramatic response to first-line
ibrutinib (30:42)
Prolonged lymphocytosis during ibrutinib therapy (33:20)
Clonal evolution in CLL; importance of monitoring for del(17p)
and p53 mutations before treatment initiation (35:35)
Sequencing of ibrutinib and venetoclax for patients with CLL;
tolerability and quality of life with ibrutinib versus venetoclax
(36:59)
Management of arthralgias associated with Bruton tyrosine
kinase (BTK) inhibitors (40:25)
Case: A woman in her mid-70s with del(13q) CLL
and no IGHV mutation receives acalabrutinib after experiencing
disease progression on multiple lines of therapy, including
ibrutinib (42:15)
BTK inhibitor-associated headaches and atrial fibrillation
(44:18)
Efficacy of ibrutinib versus acalabrutinib; ongoing Phase III
ACE-CL-006 study comparing acalabrutinib to ibrutinib for
previously treated, high-risk CLL (47:31)
Case: A man in his late 70s with del(11q) CLL
and no IGHV mutation attains a complete response and MRD-negative
status with venetoclax and obinutuzumab on the Phase III CLL14
trial (51:59)
Side effects of venetoclax/obinutuzumab (53:36)
Case: A man in his early 70s with hairy cell
leukemia (HCL) and a BRAF mutation experiences disease progression
after receiving vemurafenib as second-line therapy (57:25)
Activity and tolerability of the recently FDA-approved
antibody-drug conjugate moxetumomab pasudotox-tdfk in patients with
relapsed/refractory HCL (59:10)
Novel approaches under investigation for HCL (1:01:11)
Case: A woman in her late 50s develops
Richter’s transformation (RT) from CLL to diffuse large B-cell
lymphoma (DLBCL) after receiving ibrutinib as second-line therapy
(1:03:52)
Pathogenesis and frequency of RT in patients with
relapsed/refractory CLL (1:06:45)
Comparison of the biology of Richter’s transformed versus de
novo DLBCL; novel therapies under investigation for RT
(1:10:06)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.